Abstract
Injection drug use is the most common transmission route for hepatitis C. High rates of infection are observed among individuals on opioid agonist therapy. Although people who inject drugs carry the highest burden, few have initiated treatment. We present a comprehensive review of the evidence on the efficacy of HCV medications, drug–drug interactions, and barriers to and models of care. Studies have demonstrated comparable efficacy for individuals who are on opioid agonist therapy compared with those who are not. We propose that a strategy of treatment and cure-as-prevention is imperative in this population to curb the hepatitis C epidemic.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 347-370 |
| Number of pages | 24 |
| Journal | Infectious Disease Clinics of North America |
| Volume | 32 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jun 1 2018 |
Fingerprint
Keywords
- Best practice
- Direct acting antivirals
- Drug-drug interactions
- Hepatitis C virus
- Opioid agonist therapy
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
Cite this
Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy : A Review of Best Practice. / Norton, Brianna L.; Akiyama, Matthew J.; Zamor, Philippe J.; Litwin, Alain H.
In: Infectious Disease Clinics of North America, Vol. 32, No. 2, 01.06.2018, p. 347-370.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy
T2 - A Review of Best Practice
AU - Norton, Brianna L.
AU - Akiyama, Matthew J.
AU - Zamor, Philippe J.
AU - Litwin, Alain H.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Injection drug use is the most common transmission route for hepatitis C. High rates of infection are observed among individuals on opioid agonist therapy. Although people who inject drugs carry the highest burden, few have initiated treatment. We present a comprehensive review of the evidence on the efficacy of HCV medications, drug–drug interactions, and barriers to and models of care. Studies have demonstrated comparable efficacy for individuals who are on opioid agonist therapy compared with those who are not. We propose that a strategy of treatment and cure-as-prevention is imperative in this population to curb the hepatitis C epidemic.
AB - Injection drug use is the most common transmission route for hepatitis C. High rates of infection are observed among individuals on opioid agonist therapy. Although people who inject drugs carry the highest burden, few have initiated treatment. We present a comprehensive review of the evidence on the efficacy of HCV medications, drug–drug interactions, and barriers to and models of care. Studies have demonstrated comparable efficacy for individuals who are on opioid agonist therapy compared with those who are not. We propose that a strategy of treatment and cure-as-prevention is imperative in this population to curb the hepatitis C epidemic.
KW - Best practice
KW - Direct acting antivirals
KW - Drug-drug interactions
KW - Hepatitis C virus
KW - Opioid agonist therapy
UR - http://www.scopus.com/inward/record.url?scp=85047144147&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047144147&partnerID=8YFLogxK
U2 - 10.1016/j.idc.2018.02.001
DO - 10.1016/j.idc.2018.02.001
M3 - Review article
C2 - 29778260
AN - SCOPUS:85047144147
VL - 32
SP - 347
EP - 370
JO - Infectious Disease Clinics of North America
JF - Infectious Disease Clinics of North America
SN - 0891-5520
IS - 2
ER -